TDF/FTC Electrospun Nanofibers for Topical Prevention of HIV Transmission

Sarah Bogas\textsuperscript{a}, Maria Faria\textsuperscript{a}, Marlene Lúcio\textsuperscript{a}, Bruno Sarmento\textsuperscript{b,c}, José das Neves\textsuperscript{b,c} and Teresa Viseu\textsuperscript{a}

\textsuperscript{a}Centro de Física das Universidades do Minho e Porto (CF-UM-UP), Departamento de Física, Universidade do Minho, Braga, Portugal

\textsuperscript{b}Instituto de Investigação e Inovação em Saúde (i3S) e Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Porto, Portugal

\textsuperscript{c}CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra, Portugal

**Background**

Human immunodeficiency virus (HIV) is still a problem for global health so, there is a strong need to develop effective microbicides that can be used safely to protect from infection during sexual intercourse. This pre-exposure prophylaxis (PrEP) may be formulations containing oral or topical microbicides. Topical formulations have advantages as they are suitable for vaginal or rectal application and allow a higher local concentration of drug. It is recognized that the use of electrospun nanofibers for drug carriers is very promising in the biomedical field. So, the objective of this study is to develop a novel device for local application of antiretroviral microbicides enabling a controlled release of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), based on electrospun polymeric nanofibers.

**Methods**

Based on Truvada\textsuperscript{®}, the aim of this study is to encapsulate TDF and FTC into electrospun polymeric nanofibers. Chosen polymers were polycaprolactone (PCL) and poly(vinyl alcohol) (PVA). Nanofibers were characterized by SEM, EDS, DSC, among others. Kinetics of the release of the drugs from the fibers were studied \textit{in vitro}. By using different polymers, polymers blends and sandwich type it was tried to tailor the release of the drugs.

**Results**

Both morphological (highly porous) and mechanical properties (300% of strain) of the nanofibers were adequate for a topical delivery purpose. Drugs were successfully encapsulated in the nanofibers and their release was evaluated in different media (aqueous and micellar) and with
different methodologies (with and without dialysis bag) simulating the physiological conditions and confinement at the biological application site. Interaction with mucin revealed suitable mucoadhesiveness.

**Conclusion**
Promising results were obtained showing that it is possible to produce a tunable topical delivery system based in polymeric nanofibers.
Abstract titles: Titles should be entered in Title Case. Title case has a capital letter for the start of principal words. Do not use capital letters for prepositions, articles or conjunctions unless they start the title.

Abstract text: Abstracts should be divided in sections when submitted (background, methods, results and conclusion). Do not include section titles in the abstract text, they will be automatically inserted during the production of the abstract books. The cumulative character count of all four sections is limited to 2,000 characters total, including spaces. You may copy text from your text editing program into the relevant abstract section. Please note that special characters and formats may be lost during the pasting process, we recommend using "Arial" in your text editor before copying to reduce any errors. Please check your abstract during the Preview and edit if necessary. No tables or graphics are allowed.